CatalystMarker
← board

OKYO

Okyo Pharma Ltddistress 4/10 · elevated risk
$1.49-2%today-54% from 52w high
okyopharma.comFounded 2007London, United KingdomBiotechnology
Neurology 1
Lead: Neuropathic Pain
Revenue
pre-revenue
Liquidity
$4M
Runway
2.3 yrs
Shares 1y
0%

Price & events

-37.1% over 6M
$1.37$1.87$2.37Jan 26Apr 26Jul 262.1Mdilution: 424B5 offering (2026-02-17)dilution: 424B5 offering (2026-02-12)dilution: 424B5 offering (2026-02-11)dilution: EFFECT shelf_effective (2026-02-10)dilution: F-3 shelf_registration (2026-02-02)rating: HC Wainwright & Co.: Buy (2026-07-13)rating: Piper Sandler: Overweight (2026-02-20)
CatalystRating changeDilutionFinancingdashed = today
-2.0%
1D
+8.0%
1W
-5.7%
1M
-6.3%
3M
-32.9%
6M
-46.6%
1Y
-9.1%
2Y
—
5Y
-58.8%
All

Overview

Market Cap
$78.19M
Volume
9.79K
52 Week Range
$1.37 – $3.27
Total Shares
52.48M
Float Shares
28.01M
Short %
0.08%
% Held by Insiders
30.41%
% Held by Institutions
20.81%
RVOL
0.07x
Beta
0.04

Pipeline stages · 1 programs

OK-101 0.05%, OK-101 0.1%
Preclin›
Ph1›
Ph2›
Ph3›
Filed›
PDUFA›
Approved

Pipeline · 1 trials · 0 upcoming

ReadoutPhaseDrugIndicationEnrollStatus
2025-04-30
Phase 2OK-101 0.05%, OK-101 0.1%Neuropathic Pain18terminated

Catalyst news & presentations · 0

  • No catalyst news yet.

Approved drugs (0)

  • none — clinical-stage

Capital structure — dilution & financing

Shares out: 52,479,527 · 3 offerings/1y · 0 PIPEs
  • 2026-02-17424B5offering
  • 2026-02-12424B5offering
  • 2026-02-11424B5offering
  • 2026-02-10EFFECTshelf_effective
  • 2026-02-02F-3shelf_registration
  • 2025-06-11424B5offering
🔒 Positioning — Pro
Short interest / days-to-cover, insider buys & sells.
Upgrade to Pro
🔒 Top holders — Pro
Institutional ownership + quarter-over-quarter accumulation/trimming.
Upgrade to Pro

Wall St ratings

strong buy · target $8 (+459% upside) · 3 analysts
  • 2026-07-13HC Wainwright & Co.Buy
  • 2026-02-20Piper SandlerOverweight
  • 2025-12-08B. Riley SecuritiesBuy
  • 2025-09-23HC Wainwright & Co.Buy
  • 2025-05-05HC Wainwright & Co.Buy
  • 2025-02-18HC Wainwright & Co.Buy

Competitors — Neuropathic Pain

  • LLYELI LILLY & Co$1094.4B · D3
  • VRTXVERTEX PHARMACEUTICALS INC / MA$119.1B · D1
  • RAPPRapport Therapeutics, Inc.$1.9B · D3
  • DWTXDogwood Therapeutics, Inc.$49M · D9
  • MIRAMIRA PHARMACEUTICALS, INC.$38M · D5
  • SGMOSANGAMO THERAPEUTICS, INC$31M · D7

Recent news

Not financial advice. Data: ClinicalTrials.gov, SEC EDGAR, FINRA, Nasdaq, Yahoo.